The role of insurance status in molecular testing for thyroid nodules with indeterminate cytology
Open Access
- 1 August 2026
- journal article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (9)
Abstract
Objective: The aim of the study was to evaluate the effect of health insurance status on rate of molecular testing (MT) and subsequent thyroidectomy in patients with indeterminate thyroid nodules in a real-world high-volume clinical setting. Methods: This is a single-center, retrospective study of patients who underwent fine-needle aspiration and had Bethesda III–IV cytology results between 2014 and 2022. We excluded patients with prior thyroid cancer, thyroidectomy, or incomplete insurance data. We utilized multivariable logistic regression to identify significant predictors of MT utilization and surgical intervention; specifically examining the role of insurance status and clinical symptoms. Results: A total of 448 patients were included (median age: 52 years, 79% women) with 79% of patients undergoing MT; with an associated 27-percentage-point (34% vs 61%, P < .001) reduction in thyroidectomy. Lack of MT was the strongest predictor of surgery (adjusted odds ratios [aOR]: 4.50, 95% confidence interval [CI]: 2.71-7.47, P < .001). However, uninsured/self-pay patients had 68% lower odds of MT (aOR: 0.32, 95% CI: 0.12-0.88, P = .026) and approximately 19-percentage-point higher thyroidectomy rate compared to insured patients (59% vs 40%). Thyroid-related compression symptoms were also significantly associated with increased rate of thyroidectomy (aOR: 1.86, P = .007) and an appropriate reduction in MT utilization (aOR: 0.62, P = .046). Conclusion: Despite high MT penetration at an academic medical center, lack of health insurance poses a critical barrier to evidence-based risk stratification leading to higher rates of diagnostic lobectomy. While symptoms appropriately drove surgical management, expanding affordable MT access may mitigate barriers to care for patients with thyroid nodules.Keywords
This publication has 25 references indexed in Scilit:
- Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non–Small Cell Lung Cancer and Colorectal CancerJAMA Network Open, 2023
- Disparities in Thyroid CareEndocrinology and Metabolism Clinics of North America, 2022
- Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid NodulesJAMA Oncology, 2021
- The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision‐making from a fine‐needle aspiration sampleCancer Cytopathology, 2020
- Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate CytologyJAMA Oncology, 2019
- Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysisEndocrine Pathology, 2018
- Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid NodulesJAMA Surgery, 2018
- Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodulesCancer, 2018
- Outcomes in thyroid surgery are affected by racial, economic, and healthcare system demographicsThe Laryngoscope, 2016
- Disparity in the management of Graves' disease observed at an urban county hospital: a decade-long experienceThe American Journal of Surgery, 2012